Immunovant (IMVT) to Release Earnings on Tuesday

Immunovant (NASDAQ:IMVT) is projected to release its Q1 2026 earnings data before the market opens on Tuesday, August 5th. Analysts expect Immunovant to post earnings of ($0.69) per share for the quarter.

Immunovant (NASDAQ:IMVT) last released its quarterly earnings results on Thursday, May 29th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.08. The firm had revenue of $0.16 million for the quarter. During the same period in the prior year, the business earned ($0.52) EPS. On average, analysts expect Immunovant to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunovant Price Performance

IMVT opened at $16.76 on Tuesday. The company has a fifty day moving average price of $16.28 and a 200-day moving average price of $17.58. The firm has a market capitalization of $2.87 billion, a P/E ratio of -6.12 and a beta of 0.63. Immunovant has a one year low of $12.72 and a one year high of $34.47.

Insider Activity

In other Immunovant news, CTO Jay S. Stout sold 2,805 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $18.15, for a total transaction of $50,910.75. Following the completion of the sale, the chief technology officer directly owned 204,919 shares in the company, valued at $3,719,279.85. This represents a 1.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Michael Geffner sold 2,385 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $18.15, for a total transaction of $43,287.75. Following the transaction, the insider directly owned 221,825 shares of the company’s stock, valued at approximately $4,026,123.75. This trade represents a 1.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 7,869 shares of company stock valued at $140,384. Company insiders own 1.80% of the company’s stock.

Hedge Funds Weigh In On Immunovant

Several hedge funds and other institutional investors have recently modified their holdings of IMVT. Strs Ohio bought a new position in shares of Immunovant during the first quarter valued at about $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Immunovant by 8.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,971 shares of the company’s stock worth $708,000 after buying an additional 3,348 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Immunovant by 48.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,007,700 shares of the company’s stock worth $17,222,000 after buying an additional 329,354 shares in the last quarter. 47.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. The Goldman Sachs Group raised shares of Immunovant to a “hold” rating and set a $18.00 price objective for the company in a report on Thursday, July 10th. UBS Group lifted their price objective on shares of Immunovant from $17.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $36.40.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.